VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
SANASana Biotechnology, Inc.
$3.36$935M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksSANAEarnings History

SANA logoSana Biotechnology, Inc. (SANA) Earnings History

Net Loss

8 years of earnings data (2018–2025) · Currently unprofitable on a TTM basis

TTM Net Income
-$242M
● Net Loss
TTM EPS (Diluted)
$-0.87
Per share, diluted
YoY EPS Growth
+17.2%
Strong
Net Margin
N/A
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating MarginN/A
Gross MarginN/A
Return on Equity-118.7%
Return on Assets-53.2%
Record Annual Net Income-$13MFY2018
Record Quarterly EPS$0.09Q2 2021
Consecutive Profitable Years0years
Q1 2026
Net Income-$47M
EPS (Diluted)$-0.17
YoY Growth+17.2%Strong
QoQ Growth+19.7%Strong

Loading earnings history...

Sana Biotechnology, Inc. (SANA) Earnings Overview

As of June 23, 2026, Sana Biotechnology, Inc. (SANA) reported trailing twelve-month net income of -$242M, reflecting +17.2% year-over-year growth. The company earned $-0.87 per diluted share over the past four quarters.

Looking at the long-term picture, SANA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$13M in fiscal 2018.

Sana Biotechnology, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including FATE (-$130M net income, -2051.1% margin), CRSP (-$569M net income, -16569.8% margin), BEAM (-$65M net income, -57.2% margin), SANA has comparable earnings metrics. Compare SANA vs FATE →

SANA Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
SANA logoSANACurrent
-$242M$-0.87--118.7%+17.2%—
FATE logoFATE
-$130M$-1.08-2051.1%-51.8%+29.9%
CRSP logoCRSP
-$569M$-5.92-16569.8%-30.2%-49.1%
BEAM logoBEAM
-$65M$-0.63-57.2%-8.1%+82.3%
EDIT logoEDIT
-$109M$-1.11-395.0%-198.1%+37.5%
NTLA logoNTLA
-$395M$-3.33-609.9%-53.5%+27.4%
Best in group
Lowest in group

SANA Historical Earnings Data (2018–2025)

8 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025-$244M+8.5%-$191M$-0.96--
2024-$267M+5.8%-$273M$-1.16--
2023-$283M-5.1%-$293M$-1.46--
2022-$269M+24.3%-$273M$-1.43--
2021-$356M-24.8%-$357M$-2.14--
2020-$285M-118.2%-$161M$-1.63--
2019-$131M-887.2%-$141M$-0.70--
2018-$13M--$8M$-0.07--

Download Data

Export SANA earnings history in CSV or JSON format

Free sign-in required to download data

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

8+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

SANA — Frequently Asked Questions

Quick answers to the most common questions about buying SANA stock.

What is SANA earnings per share (EPS)?

SANA trailing twelve-month (TTM) diluted EPS is $-0.87, reflecting +17.2% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2018 to 2025 is available in the table on this page.

What is Sana Biotechnology, Inc.'s net income?

Sana Biotechnology, Inc. (SANA) trailing twelve-month net income is $-242M as of 2025. Earnings grew +17.2% year-over-year.

Is SANA profitable?

SANA is not currently profitable on a TTM basis, reporting a net loss of $-242M. Net margin is N/A. Investors should monitor for a return to profitability.

What is SANA's earnings growth rate?

SANA compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2018 to 2025.

What are SANA's profit margins?

Sana Biotechnology, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -118.7%.

Is SANA growing earnings?

Yes, SANA earnings are accelerating — EPS growth of +17.2% exceeds the 5-year CAGR of N/A. TTM net income reached $-242M. Earnings momentum is strengthening.

What was SANA's best earnings year?

Sana Biotechnology, Inc.'s highest annual net income on record is $-13M, achieved in fiscal year 2018. Earnings history on this page spans 2018 to 2025 and includes all annual and quarterly figures.

What were SANA's earnings last quarter?

SANA's most recent reported quarter was Q1 2026. Net income was $-47M with diluted EPS of $-0.17. For a full breakdown of all quarters, see the quarterly earnings table on this page.

SANA Earnings Over Time (2018–2025)

Net income & EPS — annual and quarterly view